EORTC 26053/22054 (CATNON) – Phase III trial on concurrent and adjuvant temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma.
The CATNON intergroup trial.
Both radiation therapy and chemotherapy drugs work by killing or stopping the growth of cancerous tumor cells. Radiation therapy (RT) uses high-energy x-rays to kill tumor cells and chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. The chemotherapy drug, temozolomide (TMZ), is often used to treat patients with anaplastic glioma. However, anaplastic glioma patients with specific tumor variant –1p/19q non-co-deleted tumors– are associated with lower response to chemotherapy and worse prognosis. Therefore this EORTC study assessed whether giving TMZ during and/or after radiation therapy is more effective than radiation therapy alone in treating anaplastic glioma. The interim analysis indicated that following radiotherapy with TMZ is associated with better survival benefits in patients with newly diagnosed non-co-deleted anaplastic glioma. Further analysis of the role of concurrent temozolomide treatment and molecular factors is needed.